

Special Issue

Molecular Genetics and Genomics in Neurodegenerative Diseases

Message from the Guest Editor

Neurodegenerative diseases are characterized by the progressive loss of structure or function of neurons, glial cells, and the neural networks in the brain and spinal cord, affecting people's movement, mental functioning, speech and breath. Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases. With the efforts of many researchers, some patho-mechanisms underlying these diseases have been proposed. During the past few decades, remarkable advances has been witnessed in gene sequencing technology. Genome-wide association studies have been applied to identify susceptibility genes and risk variants. The rapid development of bioinformatic technology and the reduced cost of gene sequencing enables the advances in next-generation gene sequencing. Whole-genome sequencing (WGS) and whole-exome sequencing (WES) are now widely applied in identifying rare variant genes, as well as casual and susceptibility genes in neurodegenerative diseases. The advanced technology has enabled us to identify potential therapeutic interventions for diagnosis or control of neurodegeneration.

Guest Editor

Dr. Weiran Shan

Department of Anesthesiology, University of Virginia, Charlottesville, VA 22901, USA

Deadline for manuscript submissions

closed (31 December 2023)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/159428

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,
Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.